These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 27487812

  • 1. Thrombin Activable Fibrinolysis Inhibitor in Beta Thalassemia.
    Chhikara A, Sharma S, Chandra J, Nangia A.
    Indian J Pediatr; 2017 Jan; 84(1):25-30. PubMed ID: 27487812
    [Abstract] [Full Text] [Related]

  • 2. Thrombin activatable fibrinolysis inhibitor (TAFI): relationship to hemostatic alteration in patients with beta-thalassemia.
    Mokhtar GM, Matter RM, Shawki H, Abdel Aziz MM.
    Pediatr Hematol Oncol; 2010 Aug; 27(5):363-73. PubMed ID: 20670166
    [Abstract] [Full Text] [Related]

  • 3. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
    Erem C, Nuhoglu I, Yilmaz M, Kocak M, Demirel A, Ucuncu O, Onder Ersoz H.
    J Endocrinol Invest; 2009 Feb; 32(2):169-74. PubMed ID: 19411818
    [Abstract] [Full Text] [Related]

  • 4. [Relationship between plasma levels of thrombin activatable fibrinolysis inhibitor, plasminogen activator inhibitor-1 and tissue-type plasminogen activator and deep venous thrombosis in patients with systemic lupus erythematosus].
    Liu YF, Hou N, Shi YJ, Li CX, Gao YJ, Liu LN.
    Zhonghua Yi Xue Za Zhi; 2023 Jun 06; 103(21):1638-1642. PubMed ID: 37248064
    [Abstract] [Full Text] [Related]

  • 5. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
    Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O.
    Eur J Endocrinol; 2009 May 06; 160(5):863-8. PubMed ID: 19233920
    [Abstract] [Full Text] [Related]

  • 6. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
    Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Doggen CJ, Rosendaal FR.
    Blood; 2010 Jul 08; 116(1):113-21. PubMed ID: 20385790
    [Abstract] [Full Text] [Related]

  • 7. Thalassemia major-- on the verge of bleeding or thrombosis?
    Naithani R, Chandra J, Narayan S, Sharma S, Singh V.
    Hematology; 2006 Feb 08; 11(1):57-61. PubMed ID: 16522552
    [Abstract] [Full Text] [Related]

  • 8. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Chudý P, Kotuličová D, Staško J, Kubisz P.
    Blood Coagul Fibrinolysis; 2011 Sep 08; 22(6):493-8. PubMed ID: 21519232
    [Abstract] [Full Text] [Related]

  • 9. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
    Akinci B, Comlekci A, Yener S, Demir T, Ozcan MA, Bayraktar F, Yesil S.
    Endocr J; 2007 Aug 08; 54(4):593-9. PubMed ID: 17690487
    [Abstract] [Full Text] [Related]

  • 10. Hemostatic alterations in splenectomized and non-splenectomized patients with beta-thalassemia/hemoglobin E disease.
    Tripatara A, Jetsrisuparb A, Teeratakulpisarn J, Kuaha K.
    Thromb Res; 2007 Aug 08; 120(6):805-10. PubMed ID: 17382994
    [Abstract] [Full Text] [Related]

  • 11. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism.
    Alioğlu B, Kılıç N, Şimşek E, Dallar Y.
    J Clin Res Pediatr Endocrinol; 2012 Sep 08; 4(3):146-50. PubMed ID: 22985614
    [Abstract] [Full Text] [Related]

  • 12. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
    Zorio E, Castelló R, Falcó C, España F, Osa A, Almenar L, Aznar J, Estellés A.
    Br J Haematol; 2003 Sep 08; 122(6):958-65. PubMed ID: 12956767
    [Abstract] [Full Text] [Related]

  • 13. Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays.
    Bollen L, Peetermans M, Peeters M, Van Steen K, Hoylaerts MF, Declerck PJ, Verhamme P, Gils A.
    Thromb Res; 2014 Nov 08; 134(5):1097-102. PubMed ID: 25193405
    [Abstract] [Full Text] [Related]

  • 14. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C.
    Clin Endocrinol (Oxf); 2006 Mar 08; 64(3):323-9. PubMed ID: 16487444
    [Abstract] [Full Text] [Related]

  • 15. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension.
    Małyszko J, Tymcio J.
    Pol Arch Med Wewn; 2008 Mar 08; 118(1-2):36-41. PubMed ID: 18405171
    [Abstract] [Full Text] [Related]

  • 16. Coagulation Profile at Diagnosis in Patients with Acute Lymphoblastic Leukemia.
    Sehgal S, Sharma S, Chandra J, Nangia A.
    Indian J Pediatr; 2016 Oct 08; 83(10):1082-6. PubMed ID: 27109393
    [Abstract] [Full Text] [Related]

  • 17. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
    Yener S, Akarsu M, Demir T, Akinci B, Sagol O, Bayraktar F, Ozcan MA, Tankurt E, Yesil S.
    J Endocrinol Invest; 2007 Nov 08; 30(10):810-9. PubMed ID: 18075282
    [Abstract] [Full Text] [Related]

  • 18. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.
    Erem C, Ucuncu O, Yilmaz M, Kocak M, Nuhoglu I, Ersoz HO.
    Endocrine; 2009 Feb 08; 35(1):75-80. PubMed ID: 18958631
    [Abstract] [Full Text] [Related]

  • 19. Alterations of anticoagulant proteins and soluble endothelial protein C receptor in thalassemia patients of Chinese origin.
    Huang Y, Long Y, Deng D, Liu Z, Liang H, Sun N, Xu Y, Lai Y, Cheng P.
    Thromb Res; 2018 Dec 08; 172():61-66. PubMed ID: 30384036
    [Abstract] [Full Text] [Related]

  • 20. Thrombin activatable fibrinolysis inhibitor and thrombin-antithrombin-III-complex levels in patients with gastric cancer.
    Fidan E, Kavgaci H, Orem A, Yilmaz M, Yildiz B, Fidan S, Akcan B, Ozdemir F, Aydin F.
    Tumour Biol; 2012 Oct 08; 33(5):1519-25. PubMed ID: 22535370
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.